Gilead Made Gains In Oncology, Though Virology Remains King
New Studies And Catalysts For Trodelvy And Magrolimab Anticipated In 2021
Executive Summary
Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.